HansenE, NadagoundlaC, WangC, et al.Buprenorphine for cancer pain in patients with nonmedical opioid use: A retrospective study at a comprehensive cancer center. Am J Hosp Palliat Care, 2020; 37(5):350–353.
2.
DavisMP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Supp Oncol, 2012; 10(6):209–219.
GhoshSM, KlaireS, TanguayR, et al.A review of novel methods to support the transition from methadone and other full agonist opioids to buprenorphine/naloxone sublingual in both community and acute care settings. Can J Addict, 2019; 10(4):41–50.
8.
National Clinician Consultation Center. Available from: https://nccc.ucsf.edu [Last accessed: January 9, 2023].
9.
Provider Clinical Support System Medication for Opioid Use Disorder. Available from: http://pcssnow.org [Last accessed: January 9, 2023].
10.
CohenSM, WeimerMB, LevanderXA, et al.Low dose initiation of buprenorphine: A narrative review and practical approach. J Addict Med, 2022; 16(4):399–406; doi: 10.1097/ADM.0000000000000945.
11.
ButtonD, HartleyJ, RobbinsJ, et al.Low-dose buprenorphine initiation in hospitalized adults with opioid use disorder: A retrospective cohort analysis. J Addict Med, 2022; 16(2):e105.
RandhawaPA, BrarR, NolanS. Buprenorphine–naloxone “microdosing”: An alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market. CMAJ, 2020; 192(3):E73.
14.
BeckerWC, FrankJW, EdensEL. Switching from high-dose, long-term opioids to buprenorphine: A case series. Ann Intern Med, 2020; 173(1):70–71.
15.
ThakrarAP, JablonskiL, RatnerJ, et al.Micro-dosing intravenous buprenorphine to rapidly transition from full opioid agonists. J Addict Med, 2022; 16(1):122–124.
16.
NealeKJ, WeimerMB, DavisMP, et al.Top ten tips palliative care clinicians should know about buprenorphine. J Palliat Med, 2023; 26(1):120–130; doi: 10.1089/jpm.2022.0399
